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Reaching the correct three-dimensional structure is crucial for the proper function
of a protein. The endoplasmic reticulum (ER) is the organelle where secreted and
transmembrane proteins are synthesized and folded. To guarantee high fidelity of protein
synthesis and maturation in the ER, cells have evolved ER-protein quality control
(ERQC) systems, which assist protein folding and promptly degrade aberrant gene
products. Only correctly folded proteins that pass ERQC checkpoints are allowed to
exit the ER and reach their final destination. Misfolded glycoproteins are detected
and targeted for degradation by the proteasome in a process known as endoplasmic
reticulum-associated degradation (ERAD). The excess of unstructured proteins in the
ER triggers an adaptive signal transduction pathway, called unfolded protein response
(UPR), which in turn potentiates ERQC activities in order to reduce the levels of aberrant
molecules. When the situation cannot be restored, the UPR drives cells to apoptosis.
Myelin-forming cells of the central and peripheral nervous system (oligodendrocytes
and Schwann cells) synthesize a large amount of myelin proteins and lipids and
therefore are particularly susceptible to ERQC failure. Indeed, deficits in ERQC and
activation of ER stress/UPR have been implicated in several myelin disorders, such
as Pelizaeus-Merzbacher and Krabbe leucodystrophies, vanishing white matter disease
and Charcot-Marie-Tooth neuropathies. Here we discuss recent evidence underlying the
importance of proper ERQC functions in genetic disorders of myelinating glia.
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Abbreviations: ATF, Activating Transcription Factor; BiP, Immunoglobulin Heavy Chain-Binding Protein; CH, Congenital
Hypomyelination; CHOP, C/EBP-Homologous Protein; CMT, Charcot-Marie-Tooth; CNS, Central Nervous System; CNX,
Calnexin; CRT, Calreticulin; Derlin, Degradation In Endoplasmic Reticulum; DSS, Dejerine-Sottas Syndrome; EAE,
Experimental Autoimmune Encephalomyelitis; ECD, Extracellular domain; eIF2, Eukaryotic Initiation Factor 2; ER,
Endoplasmic Reticulum; ERAD, ER-Associated Degradation; ERQC, Endoplasmic Reticulum Quality Control; GADD34,
Growth Arrest and DNA damage-inducible protein 34; GALC, Galactosylceramidase; GEF, Guanine nucleotide Exchange
Factor; GRP94/78, Glucose Regulated Protein 94/78; HMSN, HereditaryMotor and Sensory Neuropathies; HNPP, Hereditary
Neuropathy with liability to Pressure Palsy; HRD1, HMG-CoA Reductase Degradation protein 1; HSP, Heat Shock Protein;
IPN, Inherited Peripheral Neuropathies; IRE1, Inositol Requiring Enzyme 1; ISR, Integrated Stress Response; KD, Krabbe
disease; MAG, Myelin Associated Glycoprotein; MOG, Myelin Oligodendrocytes Glycoprotein; P0 or MPZ, Myelin Protein
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System; Rer1, Retention in Endoplasmic Reticulum Sorting Receptor 1; RIDD, Regulated IRE1-Dependent Decay; Sel1L,
Suppressor/Enhancer of Lin-12-like; S1P/S2P, Site 1 Protease/Site 2 Protease; UPR, Unfolded Protein Response; VCP/P97,
Valosin Containing Protein; VWMD, Vanishing White Matter Disease; XBP1, X-Box-Binding Protein 1.
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INTRODUCTION
Protein Folding and ER-Associated
Degradation (ERAD)
The endoplasmic reticulum (ER) is a cellular compartment
committed to the synthesis of secreted and transmembrane
proteins, lipid production and calcium storage. Newly
synthesized proteins co-translationally enter the ER, where they
promptly undergo processes of folding and post-translational
modification to achieve their native conformation (Hebert and
Molinari, 2007; Braakman and Hebert, 2013). Reaching a proper
structure is crucial for all proteins, since structure and function
are strictly interconnected. Indeed, aberrant conformations can
result in nonfunctional or toxic proteins, which can compromise
cell viability. Specialized surveillance systems, the ER-protein
quality control (ERQC) pathways, cooperate to guarantee high
fidelity of protein synthesis and maturation to preserve ER
homeostasis (Figure 1; Ellgaard and Helenius, 2003; Bergmann
et al., 2016). These pathways discriminate between correct
or aberrant gene products, so that only structured and fully
functional proteins are delivered to their final destination.
A cohort of ER-resident chaperones and folding enzymes co-
and post-translationally facilitate the generation of the emerging
polypeptides (Ni and Lee, 2007; Braakman and Hebert, 2013).
Classical ER chaperones, such as immunoglobulin heavy chain-
binding protein/glucose regulated protein 78 (BiP/GRP78) and
glucose regulated protein 94 (GRP94), support the spontaneous
folding of proteins acting as guidance molecules (Ni and
Lee, 2007). Numerous folding enzymes, instead, accelerate the
folding reaction and catalyze disulfide bonds oxidoreduction,
glycans addition to asparagine residues (N-glycosylation) and
protein oligomerization (Hebert and Molinari, 2007; Braakman
and Hebert, 2013). Fundamental ERQC factors are the lectin
chaperones calnexin (CNX) and calreticulin (CRT), which assist
the folding of ER-synthesized glycoproteins (Figure 1; Lamriben
et al., 2016). In the CNX/CRT cycle, the modification of the
glycan portion attached to the unfolded glycoproteins drives
the alternate dissociation and re-binding of these proteins
to the lectins, until they reach their proper structure. Then,
correctly folded glycoproteins exit the cycle and travel along
the secretory pathway toward their destination (Lamriben et al.,
2016). Instead, terminally misfolded glycoproteins are targeted to
ER-associated degradation (ERAD) for their disposal (Guerriero
and Brodsky, 2012; Olzmann et al., 2013; Xu and Ng, 2015;
Lamriben et al., 2016). In ERAD of glycoproteins, specialized
ER mannosidases remove mannose residues from the misfolded
molecules, so that they can be recognized by mannose-specific
lectins and shuttled from the ER to the cytosol. Importantly,
BiP and GRP94 have been found to interact with these ER
lectins, suggesting a role for the two chaperones in ERAD (Xu
and Ng, 2015). Following substrate recognition, a dislocation
reaction takes place, favored by multi-protein complexes (called
dislocons) that span the ER membranes (Olzmann et al., 2013).
In mammals, some key dislocon components are the scaffold
protein Suppressor/Enhancer of Lin-12-like (Sel1L), the ER
dislocation factors Derlin1, -2 and -3, and several ubiquitinating
enzymes, such as HMG-CoA Reductase Degradation protein 1
(HRD1) and gp78/autocrine motility factor receptor (AMFR).
Moreover, the cytosolic valosin containing protein (VCP)/p97
ATPase is thought to provide the energy required for the
dislocation reaction (Guerriero and Brodsky, 2012; Olzmann
et al., 2013). During dislocation, ubiquitinating enzymes
add ubiquitin moieties to the aberrant polypeptide chains.
This protein modification targets the misfolded molecules to
degradation by the proteasome in the cytosol (Christianson
and Ye, 2014; Schmidt and Finley, 2014; Livneh et al., 2016).
How misfolded non-glycosylated proteins are folded, recognized
and dislocated by the ERAD machinery is less characterized
(Bergmann et al., 2016). The ERAD and proteasomemachineries,
thus, exert a pivotal role in the quality control and clearance
of specific ER clients. When the ubiquitin-proteasome clearing
system is overwhelmed and/or misfolded proteins form insoluble
aggregates, the cells may get rid of aberrant proteins by activating
autophagy (Figure 1; Hyttinen et al., 2014; Cohen-Kaplan et al.,
2016).
The Unfolded Protein Response (UPR)
Accumulation of unstructured/misfolded proteins that exhausts
the basal quality control capacity of the ER often results in ER
stress (Ron and Walter, 2007; Wang and Kaufman, 2016). This
imbalance is frequently associated with several disease states,
such as conformational disorders, neurodegeneration and cancer,
but also to those physiological processes in which extensive
protein production is required (Wang and Kaufman, 2016).
To deal with the ER overloading, cells activate the unfolded
protein response (UPR) (Figure 1; Ron and Walter, 2007; Hetz
et al., 2015). The UPR is a pro-survival strategy aimed at
reducing the excess of misfolded proteins in the ER and re-
establishing ER homeostasis, in particular by stimulating ERQC
activities. The ER chaperone BiP is also involved in sensing
the amount of misfolded proteins in the ER and initiating
the UPR cascade (Ron and Walter, 2007). Three ER stress
sensors transduce the UPR pathways: protein-kinase RNA-
like endoplasmic reticulum kinase (PERK), inositol-requiring
enzyme 1 (IRE1) and activating transcription factor 6 (ATF6)
(Ron and Walter, 2007; Hetz et al., 2015). In normal conditions,
BiP binds to IRE1 and PERK, keeping them inactive. Under
ER stress, BiP preferentially binds the misfolded molecules and
dissociates from the two transducers allowing their activation
by oligomerization and autophosphorylation (Ron and Walter,
2007; Hetz et al., 2015). Once activated, PERK phosphorylates
the translation initiation factor eIF2α (P-eIF2α), transiently
attenuating general protein synthesis (Figure 1). Paradoxically,
this is accompanied by increased translation of the mRNA
for the transcription factor ATF4, that induces the expression
of chaperones, antioxidant-, amino acid metabolism- and
autophagy-related genes, but also anti-survival genes, such as
CHOP/Ddit3 (Ron and Walter, 2007; Hetz et al., 2015). CHOP,
a transcription factor, in turn upregulates GADD34/PPP1R15a,
a regulatory subunit of the phosphatases complex in charge of
dephosphorylating P-eIF2α and as such restarting translation
(Novoa et al., 2001). Importantly, upon nutrient starvation, UV
irradiation and viral infections, kinases other than PERK catalyze
eIF2α phosphorylation, without the concomitant activation of
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FIGURE 1 | ER quality control (ERQC) pathways. In the ER specialized protein quality control (ERQC) pathways assist the synthesis, folding and maturation of
proteins destined for secretion or insertion into the cell membrane. ER-synthesized proteins emerge from ER-bound ribosomes and reach their native structure,
guided by ER-resident chaperones, such as CNX, CRT and BiP. Proteins that fold correctly transit to the Golgi stacks to complete their maturation and are then
delivered to their final destination. Proteins that are unable to reach their native conformation, designated as “terminally misfolded,” are eliminated to counter potential
proteo-toxicity. The main degradation system in the ER is the ER-associated degradation (ERAD) pathway. In this pathway, misfolded ERAD substrates are recognized
by specialized ER lectins and dislocated from the ER to the cytosol by dedicated ERAD dislocation complexes (dislocons). In concomitance with the dislocation
reaction, ubiquitinating enzymes attach ubiquitin moieties to the aberrant polypeptide chains as a signal for proteasomal recognition. Once in the cytosol,
polyubiquitinated ERAD substrates are detected by the proteasome and degraded. Hence, basal ERQC activities cooperate to finely tune the balance between
protein production and clearance. When the ERAD/proteasome system is engulfed and/or proteins form intracellular aggregates, autophagy may be activated as an
alternative degradation system. Mutations that hamper the achievement of a proper protein structure can produce an excess of misfolded proteins in the ER, which
exhausts the basal ERQC capacities generating ER stress. Under these conditions, BiP detects the excess of misfolded proteins and initiates the unfolded protein
response (UPR) cascade, which is mediated by the PERK, IRE1, and ATF6 signaling pathways. The final goal of the UPR is to reduce the amount of misfolded
proteins in the ER and re-establish ER-homeostasis. PERK (via phosphorylation of the translation initiation factor eIF2α) attenuates global protein synthesis.
Concomitantly, activated IRE1/XBP1 and ATF6 pathways upregulate ERAD, ER-chaperones and autophagy genes, and genes associated with amino acid and lipid
metabolism. If the ER stress cannot be resolved, the UPR itself can drive cells to apoptosis.
the IRE1 and ATF6 pathways. In this way the phosphorylation
of eIF2α “integrates” a plethora of different stresses, in a response
known as the integrated stress response (ISR) (Donnelly et al.,
2013; Pakos-Zebrucka et al., 2016). The UPR-specific IRE1
and ATF6 pathways, instead, converge on the transcriptional
upregulation of ER folding chaperones and enzymes, protein
export, lipid metabolism and ERAD genes (Figure 1; Acosta-
Alvear et al., 2007; Yamamoto et al., 2007; Shoulders et al.,
2013). To orchestrate this program, two transcription factors are
recruited. One is spliced X-box binding protein-1 (XBP1s), which
is generated via the IRE1-mediated unconventional splicing of
XBP1 mRNA; the other is the cleaved cytosolic domain of ATF6
(ATF6-f fragment), produced by the S1P/S2P cleavage of the
full length ATF6 (Ron and Walter, 2007; Hetz et al., 2015).
More recently, several other mechanisms have been proposed
to contribute in reducing the protein flux into the ER upon
ER stress. These include the regulated IRE1-dependent decay
(RIDD) of ER localized mRNAs (Hollien andWeissman, 2006), a
selective mRNA release from the site of translation (Reid et al.,
2014) and a pre-emptive quality control degradation system
(Kadowaki et al., 2015). When the adaptive UPR fails and ER
stress persists, the response may switch to a terminal maladaptive
phase, leading damaged cells to apoptosis (Ron andWalter, 2007;
Hetz et al., 2015).
Proficient secretory cells, in charge of abundant protein
production, require highly efficient ERQC systems to survive
under sustained ER stress. In the central and peripheral nervous
systems (CNS and PNS), oligodendrocytes and Schwann cells
are the glial cells specialized in the formation of myelin (Monk
et al., 2015; Hughes and Appel, 2016). Myelin is a multi-
layer membrane that enwraps the axons to favor the saltatory
conduction of the nerve impulse, provide axonal protection,
allow axon-glia communication and mediate signaling with the
extracellular environment (Jessen and Mirsky, 2005; Nave and
Werner, 2014; Bercury and Macklin, 2015). In mammals, myelin
formation is a post-natal event that requires the production
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of large amounts of membrane components, such as lipids
and myelin-specific proteins. After the completion of myelin
biogenesis, Schwann cells and oligodendrocytes are committed to
preserve long-term myelin stability and functionality. Defective
myelin development (dysmyelination) or myelin instability and
its consequent degeneration (demyelination) often result in
mild-to-very severe neurological and neuromuscular disorders.
Notably, animal models carrying mutations in key ERQC factors
display CNS and PNS disease phenotypes. In addition, ERQC
failure, with subsequent ER stress and UPR activation, has been
associated with several genetic disorders of myelinating glia.
As such, the modulation of ERQC functions is emerging as a
promising target for the treatment of ER stress-related myelin
disorders. All of these aspects will be here overviewed and
discussed.
ERQC Factors and Dysmyelination
As a central site for the biosynthesis of proteins and lipids,
the ER is the organelle where many myelin components are
produced. Several transmembrane myelin proteins of both the
CNS and the PNS are synthesized on ER-bound ribosomes, post-
translationally modified and delivered to myelin within vesicles.
In the myelin sheath they often function as adhesion molecules,
connecting adjacent wraps ofmembrane (Trapp et al., 1981, 1995;
D’Urso et al., 1990; Brunden, 1992; Pareek et al., 1993, 1997;
White and Krämer-Albers, 2014). It should come as no surprise
then that the genetic ablation of factors involved in the folding
and maturation of these proteins results in severe dysmyelinating
phenotypes.
As previously discussed, BiP, member of the heat shock
protein (HSP) family, participates in various ER functions
(Hendershot, 2004; Ron and Walter, 2007; Dudek et al., 2009).
Full BiP−/− mice die at the embryonic stage, whereas BiP+/−
mice develop normally (Zhu and Lee, 2015). A number of
tissue-specific BiP knock-out mice revealed that BiP contributes
in maintaining homeostasis of different organs, including the
liver, the adipose tissue and the hematopoietic system (Zhu
and Lee, 2015). Different BiP mutant mouse models, such
as hypomorphic mutants, knock-in and conditional knock-out
mice, display neuronal death and degeneration, reduction in
brain size, cortical dysplasia, defective axon outgrowth and
severe CNS and PNS myelin abnormalities (Mimura et al.,
2008; Wang et al., 2010; Favero et al., 2013; Jin et al., 2014;
Hussien et al., 2015). In particular, the conditional ablation of
BiP either in oligodendrocytes or in Schwann cells strongly
affects myelin formation and maintenance, resulting in cell
loss, severe developmental hypomyelination (thinner myelin),
demyelination and motor defects. Of note, the oligodendrocyte-
specific ablation of BiP results in ER stress and UPR activation,
with upregulation of CHOP and increased oligodendrocytes
apoptosis in some regions of the brain. Finally, heterozygous
deletion of BiP in experimental autoimmune encephalomyelitis
(EAE) animals, a model of multiple sclerosis, exacerbates
the disease phenotype, with increased CHOP expression and
oligodendrocytes death. Altogether these observations indicate
that BiP is important in myelin physiology and is involved in
countering inflammatory demyelination (Hussien et al., 2015).
The ER lectin CNX has also been shown to be important for
the physiology of both the CNS and PNS. In fact, CNX, but not
CRT, appears to play a role in the folding of peripheral myelin
protein 22 (PMP22) and myelin protein zero (P0) in the PNS
(Figure 3; Dickson et al., 2002; Jung et al., 2011) and in the quality
control of wild-type and misfolded proteolipid protein (PLP)
(Figure 2) and myelin oligodendrocytes glycoprotein (MOG)
in the CNS (Swanton et al., 2003; Jung and Michalak, 2011;
Jung et al., 2015). In mice, the complete lack of CNX, but
not CRT, is viable, but CNX−/− mice display severe motor
impairment and myelin defects in both CNS and PNS (Mesaeli
et al., 1999; Denzel et al., 2002; Kraus et al., 2010). In cultured
CNX-deficient cells, both the folding and the adhesive function
of GFP-tagged P0 and PMP22 glycoproteins are impaired (Jung
et al., 2011). Thus, in the PNS, the dysmyelination might be
related to the lack of proper quality control of wild-type PMP22
and P0 proteins (Denzel et al., 2002; Kraus et al., 2010; Kraus
and Michalak, 2011). In addition to CNX, ERp57, an ER-resident
disulfide isomerase, has been implicated in the folding of the
disulfide-bond-containing protein P0, but not in the folding of
MOG, suggesting that different ERQC factors are involved in
the maturation and post-translational modification of different
myelin proteins (Jung et al., 2011; Jung and Michalak, 2011).
In light of these observations, it will be of great interest to
further investigate how other ERQC components, for example
members of the ERAD/proteasome machineries known to
participate in the degradation of wild-type and mutant myelin
proteins (Pareek et al., 1993, 1997; Hara et al., 2014; Lossos et al.,
2015), are involved in myelinogenesis, myelin maintenance and
disease.
ER PROTEIN QUALITY CONTROL AND
MYELIN DISEASES OF THE CNS
ERQC and Pelizaeus-Merzbacher Disease
Pelizaeus-Merzbacher disease (PMD) is a rare inherited
leukodystrophy affecting CNS myelin. The signs of PMD may
vary widely from case to case. Patients affected by classical PMD
exhibit lower limb spasticity and have a relatively normal life
span, whereas patients with the connatal form never learn to
talk or walk and have a markedly shortened life span (Hobson
and Garbern, 2012). PMD patients have a diffuse pattern
of hypomyelination in the CNS, but in most severe cases a
nearly complete absence of myelin and a profound loss of
oligodendrocytes are observed. PMD is caused by a variety of
missense, duplication and deletion mutations in the PLP1 gene
(Garbern, 2005). PLP1 is highly expressed in oligodendrocytes
and encodes two tetraspan proteins, proteolipid protein (PLP)
and its splice variant DM20. These are the most abundant
proteins in CNS myelin and play a structural role in the
formation and maintenance of the myelin sheaths (Greer and
Lees, 2002).
Several mouse models are currently available to study both
PLP function and the pathogenesis of PMD. Notably, some
missense mutations found in patients are also naturally occurring
in mice. For example, the A242V amino acid substitution, that
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FIGURE 2 | ER quality control of wild-type and mutant PLPs in oligodendrocytes. Proteolipid Protein (PLP) is the most abundant protein of CNS myelin. Wild
type PLP protein (PLPWT ) is synthesized in the ER and folded via transient and glycan-independent interaction with BiP and CNX. It then moves to the Golgi, where it
associates with lipid rafts, and finally it is targeted to myelin. PLPWT is normally degraded via the ERAD/proteasome system and/or lysosomes. Mutations in PLP result
in Pelizaeus-Merzbacher Disease (PMD), a genetic leucodystrophy that affects CNS myelin in both humans and related-mouse models. Some PLP mutants
(PLPrsh/msd/W162L/G245A ) are misfolded proteins that accumulate in the ER, stably interacting with the ER retention factors BiP and CNX. All of these mutants are
degraded via the ERAD/proteasome system, albeit with a different rate of degradation. The PLPW162L mutant can also be disposed of by lysosomes. The PLPmsd
and PLPrsh, but not the PLPW162L/G245A variants, induce the UPR response in vitro and in vivo.
causes a severe form of PMD in humans, is found in the myelin
synthesis-deficient (msd) mouse, whereas the I186T mutation,
which results in a milder disease in humans, is found in the
rumpshacker (rsh) mouse (Duncan, 2005). Another mutant, the
jimpy (jp) mouse, has been extensively used as a PMD model,
even if the same mutation is not found in humans (Baumann
and Pham-Dinh, 2001). The pathogenetic mechanism underlying
severe PMD caused by missense mutations is likely a gain of
toxic function of PLP mutants. In fact, individuals with null PLP
mutations present a less severe form of the disease (Garbern
et al., 1997), and similarly, PLP1 knock-out mice display a milder
phenotype as compared to msd or rsh mice (Klugmann et al.,
1997). Finally, in jpmice the dysmyelination and oligodendrocyte
death are not corrected by transgene-driven expression of wild-
type PLP and DM20 (Nadon et al., 1994; Schneider et al., 1995).
Wild-type PLP (PLPWT) is synthesized in the ER and
subsequently transported to the Golgi complex, where it
associates with myelin lipids into rafts before reaching the cell
surface (Lee, 2001). Most of the PLPWT is degraded via the
lysosomal pathway, although a minor fraction may also be
degraded by the proteasome (Figure 2; Roboti et al., 2009).
Interestingly, data obtained in various in vitro and in vivo PMD
models demonstrate that the PLP mutant proteins do not reach
the cell surface but accumulate in the ER (Gow et al., 1994, 1998;
Gow and Lazzarini, 1996; Krämer-Albers et al., 2006; Roboti
et al., 2009; Numasawa-Kuroiwa et al., 2014) and studies using
conformationally-sensitive antibodies show that these point
mutations cause PLP misfolding (Jung et al., 1996; Southwood
and Gow, 2001). Remarkably, mutations inducing a complete
arrest of PLP/DM20 trafficking in the ER are associated with
the most severe form of the disease and with oligodendrocyte
death (connatal PMD), whereas mutations resulting in a partial
block of PLP and/or DM20 trafficking are associated with milder
disease phenotype (classical PMD) (Gow and Lazzarini, 1996;
Southwood and Gow, 2001). Several mechanisms have been
proposed to explain the ER retention of misfolded PLP mutants.
Abnormal intramolecular cross-links formed by exposure of
unpaired cysteine residues might contribute to mutant PLP
misfolding and ER retention (Dhaunchak and Nave, 2007).
Moreover, the A242V mutant of PLP (PLPmsd) stably interacts
with the ER chaperones BiP and CNX, which may act as ER
retention factors (Figure 2; Swanton et al., 2003). In particular,
CNX stably binds to a transmembrane domain of mutant
PLPmsd (but not to wild-type PLP) and retards its degradation
(Swanton et al., 2003). The extent of mutant PLP accumulation
in the ER may also correlate to its degradation rate. It has
been observed that ER-retained PMD mutants, for example
PLPmsd, PLPW162L, and PLPG245A variants, are degraded by the
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proteasome via ERAD (Figure 2 and Table 1; Krämer-Albers
et al., 2006; McLaughlin et al., 2006; Roboti et al., 2009). Notably,
the PLPmsd variant, that causes severe PMD, was found to be
more stable than the PLPW162L and PLPG245A mutants, which
cause a milder disease (Roboti et al., 2009). This suggests that
higher resistance to ERADmay contribute in determining amore
severe manifestation by increasing the accumulation of mutant
PLPmsd in the ER (Roboti et al., 2009). The ER retention of
misfolded PLP proteins can also induce the UPR, as observed
in some PMD models including transfected cells, mouse models
and in post-mortem specimen from a PMD patient (Hudson and
Nadon, 1992; Southwood and Gow, 2001; Southwood et al., 2002,
2013; McLaughlin et al., 2007; Roboti et al., 2009). Interestingly,
Roboti et al. reported that the “aggressive” PLPmsd mutant
appears to induce a strong increase of XBP1s and CHOP mRNA
levels, whereas the expression of the less “aggressive” mutants
(PLPW162L and PLPG245A) fails to upregulate these UPR markers
(Roboti et al., 2009), implying a possible correlation between
UPR activation and disease severity. However, such a clear
correlation is not observed in other studies, where the expression
of the PLPrsh variant (I186T mutation), associated with a mild
disease phenotype, is sufficient to activate the UPR (Southwood
et al., 2002; McLaughlin et al., 2006). Thus, the molecular
mechanisms explaining the difference between mild and severe
PLP mutants still remain partially unclear. Interestingly, a recent
study reported that a proinflammatory environment might be
an additional factor that participate to PMD pathogenesis and
may contribute to disease severity (Southwood et al., 2013).
The pathogenetic mechanism proposed in PMD may also apply
to disorders clinically related to PMD caused by mutations in
myelin genes other than PLP1. Indeed, a missense mutation in
the myelin associated glycoprotein (MAG) gene, which induces
a PMD-like disorder, affects MAG folding and prevents its
transport to the cell surface. The mutant protein accumulates in
the ER, interacts with BiP and CNX and is subjected to ERAD
(Table 1; Lossos et al., 2015). This suggests that the ER retention
may represent a common pathogenetic mechanism in PMD and
PMD-like disorders.
One crucial question for understanding PMD pathogenesis is
why protein accumulation in the ER and the subsequent UPR
activation is deleterious for oligodendrocyte function or survival.
Few studies have tried to manipulate supposed pro-apoptotic
factors of the UPR, such as CHOP, ATF3 or Caspase12 in PMD
mouse models and led to rather surprising conclusions. While
ablation of ATF3 or Caspase12 has only minor effect on disease
severity both in msd and rsh mice (Sharma and Gow, 2007;
Sharma et al., 2007), the genetic ablation of CHOP dramatically
worsens the disease phenotype in rsh mice (Southwood et al.,
2002). In fact, rsh/Chop−/− mice die as early as 5 weeks of
age and exhibit frequent seizures following handling or sudden
noises as compared to rsh mice that have a normal life span.
This extreme exacerbation of the phenotype is accompanied by
an increase of oligodendrocyte apoptosis in the spinal cord and
in the optic nerve (Southwood et al., 2002). These data indicate
that CHOP activation attenuates PMD severity and protects
oligodendrocytes from apoptosis, supporting the idea that the
CHOP arm of the UPR has an adaptive role in PMD. The
mechanisms underlying oligodendrocytes death in these models
still remain elusive. This also opens questions on the role of
CHOP in myelin disorders. Indeed numerous studies carried
out in the CNS and the PNS (see below) do not support a
role for CHOP in apoptosis, but suggest it should be viewed
as a mediator of responses to stress (Gow and Wrabetz, 2009).
Consistently, a recent study shows that CHOP overexpression
in oligodendrocytes and Schwann cells of wild-type, msd and
rsh mice does not influence animal life span or oligodendrocytes
apoptosis (Southwood et al., 2016). Interestingly, the authors
report that only half of myelinating oligodendrocytes from
rsh mice expresses CHOP and propose that myelinating cells
expressing PLP mutants alternate periods of active UPR, with
subsequent attenuation of protein synthesis, and periods of
inactive UPR and increased metabolism, leading to myelin
production. In this view, cells switching off the UPR may be
more vulnerable to pro-death signals due to the re-activation
of the metabolism, such as calcium release or ROS production
(Southwood et al., 2016). Further experiments performed at a
single-cell level should be performed to confirm this model.
ERQC in Krabbe Disease
Krabbe disease (KD), also known as globoid cell leukodystrophy,
is an autosomal recessive disorder characterized by rapid, fatal
neurodegeneration associated with an extensive demyelination in
both the CNS and PNS. Patients usually present an early-infantile
phenotype in the first 6 months of life with irritability, spasticity,
developmental delay, and progress to severe motor and mental
deterioration that lead to death in childhood (Wenger et al.,
2000). In addition to this early presentation, late-adult onset and
milder variants exist, which progress more slowly (Wenger et al.,
2000). Most of the KD hallmarks, such as severe demyelination,
loss of oligodendrocytes, globoid cell infiltration and premature
death are recapitulated in the twitcher (twi) mouse, a naturally
occurring mutant (Kobayashi et al., 1980; Suzuki and Suzuki,
1983). All forms of KD are caused by mutations in the lysosomal
enzyme galactosylceramidase (GALC) (Suzuki and Suzuki, 1970)
that is essential for the hydrolysis of galactolipids, including
galactosylsphingosine (psychosine) and galactosylceramide, a
major lipid component of CNS and PNS myelin. In cells from
KD patients, GALC activity is very low (0–5% of normal activity)
and this leads to a progressive accumulation of psychosine,
which is cytotoxic to oligodendrocytes and Schwann cells
(Won et al., 2016). However, it should be noted that a recent
work has questioned the relationship between psychosine and
oligodendrocyte death in twi mice (Zhu et al., 2016). Over
100 deletion, frameshift and missense mutations in the GALC
gene have been associated with KD (Won et al., 2016), but the
correlation between GALC mutations and the clinical outcomes
(age of onset or survival) is unclear and, even for the same
mutation, a considerable clinical variability has been observed
(Wenger et al., 2000). Similarly, measurement of GALC activity
on whole-cell lysates does not reliably predict the severity of
KD (Jardim et al., 1999). This difficulty to establish genotype-
phenotype relationships is a major hurdle for current and future
therapies against KD.
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Newly synthesized GALC is co-translationally translocated
into the ER and glycosylated in the Golgi apparatus (Spratley
and Deane, 2016). GALC is then recognized by the mannose-
6-phosphate receptor, which targets it to the lysosome either
directly from the trans-Golgi network or indirectly via secretion
and re-uptake (Nagano et al., 1998; Spratley and Deane, 2016).
Once in the lysosome, GALC is cleaved into 50 and 30 KDa
subunits and processes its lipid substrates. Mutations associated
with KDwere shown to strongly alter GALC trafficking (Table 1).
The L629R mutation causes a severe lack-of-secretion phenotype
and accumulation in the ER, whereas the GALCI243T and
GALCD528N mutants are secreted into the medium but their
reuptake is impaired (Lee et al., 2010). Moreover, the GALCD528N
mutant was found to be hyperglycosylated and misfolded and
its function can be partially rescued by a treatment with the
pharmacological chaperone α-lobeline (Lee et al., 2010). Another
study confirmed that many GALC mutants were trapped within
the ER instead of reaching the lysosome (Spratley et al., 2016).
These data suggest that failure of ERQC is an important
determinant in KD pathogenesis.
A recent work has proposed new mechanisms that may
explain the considerable variability between KD patients (Shin
et al., 2016). In this study, the authors show that cells expressing
GALC mutants associated with infantile KD have no lysosomal
GALC activity, whereas cells expressing late-onset mutations
have a small residual activity in the lysosomes. Importantly,
GALC trafficking to the lysosome is consistently impaired in
infantile-onset mutants, but not (or to a lesser extent) in late-
onset mutants. GALC activity is also detected in the ER and
accounts for a substantial part of total GALC activity in the
mutants, thus precluding total GALC activity to be a reliable
marker of KD severity. The authors also suggest that three
polymorphisms present in the GALC coding region (c.550T,
c.742A, and c.1685C), which are not disease-causing per se,
couldmodulate the impact of KD associated-mutations onGALC
levels, activity and trafficking. In fact these additional amino acids
changes in GALC sequence can further increase ER retention of
KD mutants and/or reduce their activity, although the molecular
bases of this process are currently unknown. The authors next
propose a model for predicting KD severity: if patient-derived
cells have less than 5% of normal GALC activity this indicates
that the patient has KD. If the residual GALC activity is located
in the lysosome, then the patient will have a late-onset disease
with milder phenotype; if most of the remaining GALC activity
is found in the ER or Golgi, then the patient will have an
infantile-onset disease and a severe phenotype (Shin et al., 2016).
These results support the concept that impaired trafficking to
the lysosome is an important feature for predicting the severity of
KD and that boosting the ERQC by pharmacological chaperones
could alleviate KD defects. Activation of the UPR has not been
reported yet in KD.
ER Stress and Vanishing White Matter
Disease
Vanishing white matter disease (VWMD) is one of the
most prevalent inherited childhood white matter disorders
(Bugiani et al., 2010). VWMD is clinically characterized by
slowly progressive cerebellar ataxia, spasticity and mild mental
retardation that can worsen dramatically after episodes of stress,
such as febrile infections, minor head trauma and acute fright
(van der Knaap et al., 2006). The disease progresses rapidly
and most patients die within few years after disease onset.
Variation in disease severity is extremely wide: severe forms
start during infancy and lead to premature death, while milder
variants start in adolescence or adulthood and are characterized
by slow disease progression (van der Knaap et al., 2006).
VWMD is characterized by a severe deterioration of white
matter, which shows diffuse vacuolation, myelin loss, presence
of oligodendrocytes with abundant “foamy” cytoplasm and
dysmorphic astrocytes (Bugiani et al., 2010). While apoptotic
oligodendrocytes are observed in some affected areas, general
oligodendrocytic density increases as a result of elevated pre-
myelinating oligodendrocytes proliferation (Van Haren et al.,
2004; Bugiani et al., 2011).
VWMD is caused by mutations in any of the five genes
encoding the subunits of eukaryotic initiation factor 2B (eIF2B),
which is pivotal for translation of mRNAs into proteins (van
der Knaap et al., 2002). At least 120 different mutations have
been described and approximately 90% are missense mutations
(Bugiani et al., 2010). eIF2B serves as a guanine nucleotide
exchange factor (GEF) of eIF2. The eIF2-GTP complex loads
the initiator methionyl-tRNA (Met-tRNAi) to the ribosome
upon recognition of the start codon of the mRNA. The eIF2-
bound GTP is then hydrolyzed, with consequent release of
eIF2 in its inactive GDP-bound form, which is ready for
another round of translation initiation. As mentioned earlier,
the α subunit of eIF2 is phosphorylated under various stress
conditions. P-eIF2α converts eIF2 from a substrate of eIF2B
to a strong competitor, thus reducing the formation of the
eIF2-GTP complex and leading to a general attenuation of
protein synthesis. As observed in patient-derived cells, almost
all mutations associated with VWMD reduce the eIF2B GEF
activity (Fogli et al., 2004; Horzinski et al., 2009). However,
no correlation between residual GEF activity and disease
severity has been found (Horzinski et al., 2009; Liu et al.,
2011).
VWMD exclusively affects white matter of the brain, whereas
gray matter and other organs are spared. One obvious question is
why glial cells in the CNS are the most vulnerable to decreased
eIF2B activity. The definitive answer is not known but, due
to the central position of eIF2 in stress responses, it is likely
that mutant eIF2B modulates the ability of oligodendrocytes
to regulate protein synthesis in response to stress. Indeed,
analysis of brain tissue from VWMD patients indicates that
all three branches of the UPR are activated. Increased levels
of XBP1s, BiP, CHOP, and GADD34 mRNAs are detected
in brain autopsy samples from VWMD patients, as well as
increased immunostaining for XBP1, ATF6, BiP, ATF4 and
CHOP in oligodendrocytes and astrocytes (van der Voorn
et al., 2005; van Kollenburg et al., 2006). Consistently, primary
fibroblasts from VWMD patients are hypersensitive to ER-
stress induced by a pharmacological agent (Kantor et al.,
2005) and expression of VWMD-associated eIF2B mutants in
oligodendroglial-derived cells upregulates ATF4, GADD34 and
BiP even in the absence of a pharmacological stress agent (Kantor
et al., 2008).
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Several mouse models of VWMD have been generated in
the last few years. Knock-in mice with authentic human R132H
point mutation into Eif2b5 gene display attenuated eIF2B activity
in the brain and delayed development of white matter (Geva
et al., 2010). However, these mutant mice do not exhibit
most of the VWMD hallmarks, such as severe histological
abnormalities, activation of the ER stress response and premature
death (Geva et al., 2010; Marom et al., 2011), limiting their
value for understanding KD pathogenesis. Using a completely
different approach, Lin et al. have generated a mouse line
that recapitulates most VWMD features. They have generated
transgenic mice in which PERK signaling is specifically activated
in oligodendrocytes in an inducible manner (Lin et al., 2013).
Activation of PERK signaling in adult healthy animals is not
detrimental to oligodendrocytes or myelin (Lin et al., 2013).
In contrast, induction of PERK signaling in young animals
(from P10) suppresses eIF2B activity and leads to a VWMD-like
phenotype including severe hypomyelination, presence of foamy
oligodendrocytes, animal trembling and death by P24 (Lin et al.,
2014). These striking results demonstrate that chronic activation
of PERK signaling in oligodendrocytes during myelin formation
is pathogenic per se. In VWMD, it is plausible that eIF2B
mutants have a lower translational activity that mimics a chronic
phosphorylation of eIF2α and leads to a global attenuation of
protein synthesis and/or a reprogramming of transcription by
ATF4. Activation of this program in oligodendrocytes is likely
not compatible with the production of the large amount of ER-
synthesized proteins and lipids required for the myelination
process. In this view, further inhibition of eIF2B by additional
stresses (e.g., febrile infections) that increase eIF2α kinases
activity (e.g., PKR) may exacerbate the VWMD phenotype.
However it remains unclear how the reduced activity of eIF2B
activates the IRE1 and ATF6 branches of the UPR as observed
in VWMD patients (van der Voorn et al., 2005; van Kollenburg
et al., 2006). Intriguingly, a recent study shows that cells
expressing VWMD eIF2B mutants, despite having an enhanced
ISR, do not tolerate an additional mutation preventing eIF2α
phosphorylation (Sekine et al., 2016), although the mechanisms
for this dependence are still unclear. This underlies that the link
between VWMD and the UPR is extremely complex and needs
further investigations.
Other data suggest that also astrocytes have a pivotal
role in VWMD pathogenesis. Indeed, cultured astrocytes,
but not oligodendrocytes derived from a VWMD patient,
show defective development, aberrant morphology and
antigenic phenotypes (Dietrich et al., 2005). Consistently,
in oligodendrocytes/astrocytes co-cultures, it was observed
that VWMD astrocytes, obtained from mice carrying R484W
point mutation in Eif2b4 gene, secrete factors that inhibit
oligodendrocyte maturation, whereas wild-type astrocytes
allow normal maturation of VWMD oligodendrocytes (Dooves
et al., 2016). Altogether these results give the first evidence that
eIF2B mutations impair differentiation and stress responses
efficiency of myelinating and non-myelinating glial cells. The
molecular bases of VWMD and in particular the role of the
UPR in oligodendrocytes and astrocytes needs to be further
explored.
ERQC AND CHARCOT-MARIE-TOOTH
(CMT) NEUROPATHIES
Inherited peripheral neuropathies (IPNs) are a group of
disorders characterized by progressive degeneration of peripheral
nerves. They have a frequency of 1:2500 with extensive
clinical/genetic heterogeneity and no cure is currently available.
The largest group of IPNs includes hereditary motor and
sensory neuropathies (HMSN) or Charcot–Marie–Tooth (CMT)
diseases, with the most severe forms also known as Dejerine-
Sottas syndrome (DSS) and congenital hypomyelination (CH)
(Baets et al., 2014; Jerath and Shy, 2015). At least 80 different
genes have been linked to IPNs/CMTs, many of which are
important for proper synthesis, structure and function of the
myelin sheath (Brennan et al., 2015). Mutations in P0, PMP22
and Connexin32 (Cx32), the main structural proteins of PNS
myelin, altogether represent the vast majority of all CMT cases
(Jerath and Shy, 2015). Some Cx32 mutants display abnormal
trafficking and do not reach the cell membrane, but accumulate
in the ER/Golgi and undergo endosomal and proteasomal
degradation (Deschênes et al., 1997; VanSlyke et al., 2000; Yum
et al., 2002). However the impact of this retention on ERQC
and its link to CMT pathogenesis has not been investigated yet
(Kleopa et al., 2012). On the other hand, a number of mutations
in P0 and PMP22 proteins have been extensively shown to
generate misfolded molecules that exhaust the ERQC capacities
(Figure 3 andTable 1). These aberrant molecules remain trapped
in the ER, induce ER stress and eventually activate the UPR
(D’Antonio et al., 2009; Lin and Popko, 2009; Clayton and Popko,
2016). The role of ERQC systems in this subset of ER stress-
related neuropathies is discussed below.
PMP22-CMT1A and CMT1E
PMP22 is a transmembrane glycoprotein that accounts for the 2–
5% of the total myelin proteins in the PNS (Snipes et al., 1992; Li
et al., 2013). It is encoded by the PMP22 gene, and contains four
putative transmembrane (TM) domains and one N-glycosylation
site (Li et al., 2013). PMP22 protein is synthesized and modified
in the ER/Golgi compartments and then delivered to myelin
(Pareek et al., 1993, 1997; D’Urso et al., 1998). Interestingly, up
to 70% of the newly synthesized PMP22 is rapidly degraded by
the proteasome and only a very small amount reaches the cell
surface (Figure 3A) (Pareek et al., 1993, 1997; Notterpek et al.,
1999; Ryan et al., 2002).
Altogether, mutations in the human PMP22 gene represent
over 50% of all CMTs (Li et al., 2013). Duplication of
the chromosomal region containing the PMP22 gene is
associated with the autosomal dominant demyelinating CMT1A
neuropathy (Lupski et al., 1991), themost common form of CMT.
Point mutations in PMP22 sequence result either in hereditary
neuropathy with liability to pressure palsy (HNPP) or in the
demyelinating neuropathy known as CMT1E, which accounts for
1–5% of all CMTs (Li et al., 2013). The most extensively studied
models of CMT1E andDSS are the Trembler (Tr) and Trembler-J
(TrJ) mice, which carry the spontaneous G150D and L16P point
mutations, respectively, also found in patients (Valentijn et al.,
1992; Suter et al., 1992a,b).
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FIGURE 3 | ER quality control of wild type and mutant PMP22 (A) and P0 (B) glycoproteins in Schwann cells. Peripheral myelin protein 22 KDa (PMP22) and
myelin protein zero (P0) are glycoproteins expressed by myelinating Schwann cells in the PNS and normally located in compact myelin. Both PMP22 and P0 are
synthesized on ER-bound ribosomes, folded via transient interaction with CNX, N-glycosylated and delivered to PNS myelin after transition within the Golgi stacks
(A,B). Up to 70% of newly synthesized wild type PMP22 (PMP22WT ) is degraded by the proteasome (A). Mutations in PMP22 and P0 are associated with different
forms of Charcot-Marie-Tooth (CMT) neuropathy in both humans and mice. A subset of these mutations, such as the Trembler (G150D)/Trembler-J (L16P) mutations
in PMP22 and the S63del and R98C mutations in P0, produce misfolded proteins that accumulate in the ER-Golgi (A,B). Both PMP22TrJ and PMP22Tr variants have
been reported to engulf the ERAD/proteasome system and form cytoplasmic aggresomes, partially cleared by autophagy (A). Oppositely, neither the P0S63del nor the
P0R98C proteins form intracellular aggregates (B). Whether ERAD and/or autophagy are involved in the disposal of these P0 mutants demands investigation. Notably,
both the P0S63del/R98C and the PMP22TrJ variants (but not the PMP22Tr protein), activate the UPR response in vitro and in vivo (A,B). The P0S63del protein (and the
PMP22 mutants) also appears to exert a dominant negative effect on its corresponding wild type protein, trapping it in the ER and reducing its level in the myelin
membrane (B).
These PMP22 mutants are misfolded proteins that appear
to be stacked in the ER/Golgi and cytosolic compartments in
cultured cellular systems, in mice and in human nerve biopsies
(Naef et al., 1997; Colby et al., 2000; Hanemann et al., 2000;
Ryan et al., 2002; Fortun et al., 2003; Shames et al., 2003). The
mutant PMP22TrJ protein engulfs the ERAD/proteasome system
in Schwann cells, resulting in reduced proteasomal efficiency.
The excess of PMP22TrJ leads to the formation of aggresomes
in the cytosol, that colocalize with heath shock protein (HSP)
chaperones, proteasomes and autophagic markers (Hanemann
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TABLE 1 | Evidence of ERQC involvement and failure in genetic disorders of myelinating glia caused by ER-retained proteins.
CNS
Protein Mutation Disease BiP/CNX Degradation Aggregates Activated UPR Effect of OL
Interaction pathway formation markers CHOP ablation Apoptosis
PLP A242V (PLPmsd) PMD (Connatal) CNX/BiP ERAD/ Proteasome No CHOP, BiP, XBP1s, ATF3,
caspase 12
N.D. +++
I186T (PLPrsh ) PMD (Classical) N.D. ERAD/ Proteasome No CHOP, BiP, XBP1s, ATF3,
caspase 12
PMD Worsening + or +++*
G245A (PLPG245A ) PMD (Classical) N.D. ERAD/ Proteasome No No N.D. N.D.
W162L (PLPW162L ) PMD (Classical) N.D. ERAD/
Proteasome/
Lysosome
No No N.D. N.D.
MAG S133R (MAGS133R ) PMD-like CNX/BiP ERAD/ Proteasome N.D. N.D. N.D. N.D.
GALC T529M (GALCT529M ) KD N.D. N.D N.D N.D N.D N.D.
G286D (GALCG286D) KD N.D. N.D N.D N.D N.D N.D.
PNS
Protein Mutation Disease BiP/CNX Degradation Aggregates Activated UPR Effect of SC
Interaction pathway formation markers CHOP ablation Apoptosis
PMP22 L16P (PMP22TrJ) CMT1E CNX/ Rer1** ERAD/
Proteasome/
Autophagy
Yes BiP, CHOP, XBP1s, ATF3 N.D. +
G150D (PMP22Tr) DSS CNX ERAD/ Proteasome Yes N.D. N.D. +
P0 S63del (P0S63del ) CMT1B BiP? N.D. No CHOP, BiP, XBP1s,
ATF6-f, P-eIF2a, ATF4,
GADD34, ATF3
CMT1B
Amelioration
+
R98C (P0R98C) DSS N.D. N.D. No BiP, CHOP, XBP1s, ATF6-f None +
OL, Oligodendrocytes; SC, Schwann cell; N.D., Not Determined; *, Depending on genetic background; **, Golgi retention.
et al., 2000; Ryan et al., 2002; Fortun et al., 2003, 2005). In TrJ
mice, activated autophagy has been proposed to exert a relevant
role in the clearance of these intracellular aggregates (Figure 3A
and Table 1; Fortun et al., 2003, 2007). Aggresomes have also
been observed upon PMP22 mutations other than L16P and
G150D and in a model of CMT1A with overexpression of wild-
type PMP22 due to 7 extra-copies of the gene (Shames et al.,
2003; Liu et al., 2004; Fortun et al., 2006). However, in CMT1A
patients that carry only three copies of the wild-type gene, PMP22
aggresomes were not detected (Hanemann et al., 2000). Recently,
Hara and colleagues further explored the mechanism through
which the mutant PMP22TrJ and PMP22Tr are retained in the ER
and are polyubiquitinated (Hara et al., 2014). The authors found
that both the CNX-dependent ERQC and the Rer1-mediated
Golgi quality control systems are involved in the retention of
PMP22TrJ, but not PMP22Tr protein, despite all PMP22 variants
(including the wild-type) interact with both Rer1 and CNX
(Dickson et al., 2002; Hara et al., 2014). Furthermore, different
ubiquitinating enzymes appear to mediate the polyubiquitination
and degradation of the two mutants. While the ubquitin-ligase
HRD1 is required for both molecules, gp78 is more specific for
the PMP22Tr form (Hara et al., 2014). Hence, this work elegantly
underlies how different mutations in the very same molecule can
engage different ERQC players to be disposed. Since, in parallel to
autophagy, the ERAD pathway is fundamental for the clearance
of the PMP22 mutants, the enhancement of ERAD might
mitigate their cytotoxic effects (Hara et al., 2014). Curiously, even
though both PMP22TrJ and PMP22Tr variants are ER retained,
evidence for UPR activation has been so far reported only in TrJ
mice, but not in Tr animals (Giambonini-Brugnoli et al., 2005;
Okamoto et al., 2013). This suggests that the role of the UPR in
CMT1E needs to be further investigated.
P0–CMT1B
A member of the immunoglobulin-like superfamily, P0 (28–
30KDa) is codified as a type I transmembrane protein from the
MPZ gene (D’Urso et al., 1990; You et al., 1991; Hayasaka et al.,
1993). Abundantly and specifically expressed by myelinating
Schwann cells, P0 protein alone represents 20–50% of all PNS
myelin proteins (Everly et al., 1973; Greenfield et al., 1973;
Patzig et al., 2011). Its main, but not exclusive, functions are
to promote myelin compaction during myelinogenesis and to
preserve myelin stability during adulthood, acting as an adhesion
molecule (D’Urso et al., 1990, 1999; Filbin et al., 1990; Giese et al.,
1992; Martini et al., 1995). Like PMP22, P0 is synthesized and
processed in the ER/Golgi compartments, sorted into specific
vesicles and transported to compact myelin (Figure 3B; Trapp
et al., 1981, 1995; Brunden, 1992). The mature P0 protein is N-
glycosylated and carries a stabilizing disulfide bond, together with
other post-translational modifications (Eichberg, 2002).
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Over 200 mutations in the human MPZ gene are known to
cause up to 10% of all CMT cases. Different types of mutations,
even those affecting the very same amino acid, result in different
neuropathies, ranging from dys/demyelinating CMT1B/DSS/CH
diseases to axonal CMT2 (Shy, 2006; Timmerman et al., 2014;
Sanmaneechai et al., 2015). A subset of P0 mutations associated
with altered P0 trafficking have been described, among which
the best characterized are the R98C and S63del mutations
in the extracellular domain of P0 (P0-ECD) (Figure 3B and
Table 1; Shames et al., 2003; Khajavi et al., 2005; Wrabetz et al.,
2006; Grandis et al., 2008; Prada et al., 2012; Saporta et al.,
2012). In humans the R98C mutation results in severe early
onset dysmyelinating and demyelinating neuropathy, partially
recapitulated in R98C knock-in mice (Gabreëls-Festen et al.,
1996; Bai et al., 2006; Saporta et al., 2012). The S63del mutation
instead is associated with a milder form of CMT1B characterized
by thinner myelin and late-onset demyelination, reproduced in
S63del transgenic mice (Kulkens et al., 1993; Gabreëls-Festen
et al., 1996; Wrabetz et al., 2006; Miller et al., 2012). Both these
mutations cause their corresponding disease in heterozygous
state in humans and either heterozygous (R98C) or hemizygous
(S63del) state in mice, mimicking the dominant inheritance
and underling a gain of toxic function mechanism. Indeed,
both the P0R98C and the P0S63del proteins are misfolded and
retained in the ER, where they cause ER stress and trigger
a canonical UPR (Wrabetz et al., 2006; Pennuto et al., 2008;
Miller et al., 2012; Saporta et al., 2012; D’Antonio et al., 2013).
Altered polarity of the β-strand C in the P0-ECD carrying
the S63del mutation is thought to be the structural aberration
responsible for ER retention and UPR activation, likely because
it promotes P0S63del binding to BiP (Wrabetz et al., 2006). In
addition, the mutant P0S63del protein has also been proposed to
exert a dominant negative effect on the wild-type P0 (P0WT), by
partially trapping it into the ER and reducing its myelin levels
(Figure 3B; Fratta et al., 2011). In both S63del and R98Cmice, the
activated UPR induces the expression of the pro-apoptotic factor
CHOP. Intriguingly, the genetic ablation of CHOP ameliorates
the neuropathic phenotype in S63del mice, whereas it has no
effects in R98C animals (Pennuto et al., 2008; Saporta et al.,
2012). What causes this difference? The main clinical feature
of R98C mice is severe developmental hypomyelination without
significant demyelination, whereas S63del mice display a milder
hypomyelination followed by demyelination. The ablation of
CHOP in S63del mice rescues demyelination and motor defects,
but not hypomyelination, which may partially explain the lack of
effects in R98C mice. Importantly, despite high levels of CHOP,
neither S63del nor R98C nerves show significantly increased
apoptosis, suggesting that CHOP may exert a different function
in Schwann cells (Pennuto et al., 2008; Saporta et al., 2012). For
example, in S63del mice the detrimental role of CHOP appears
to be related to the upregulation of GADD34, that drives the
dephosphorylation of P-eIF2α and restarts protein translation
under a chronic ER stress (D’Antonio et al., 2013). In line with
this, prolonging the attenuation of protein synthesis by genetic
or pharmacological inhibition of GADD34 alleviates the S63del-
CMT1B disease more efficiently than CHOP ablation, with
improved hypomyelination, demyelination, motor performance
and neurophysiological parameters (D’Antonio et al., 2013; Das
et al., 2015). Whether GADD34 inhibition and prolonged eIF2α
phosphorylation may improve also the R98C neuropathy is
an interesting hypothesis that deserves testing. Surprisingly,
and opposite to what was expected, the ablation of PERK in
S63del nerves ameliorates, rather than aggravates, the neuropathy
phenotype, despite decreased levels of P-eIF2α. This raises the
intriguing possibility that PERK might have other effects on
the neuropathy, uncoupled from the UPR and the attenuation
of protein translation (Musner et al., 2016; Sidoli et al., 2016).
It should also be noted that, despite the sustained ER stress,
S63del Schwann cells manage to myelinate (albeit to a lower
extent) and survive, indicating that significant UPR-related
adaptive mechanisms are also in place to counter protein toxicity.
Differently from what was observed in TrJ mice, in S63del mice
neither cytoplasmic aggresomes nor autophagy genes induction
have been detected, whereas ER chaperones and ERAD genes are
strongly induced (Pennuto et al., 2008; D’Antonio et al., 2013).
A better understanding of how these ERQC systems intervene
in the recognition, folding and clearance of the mutant P0
will be of great relevance for the design of effective therapies.
Curiously, despite CHOP, GADD34, and PERK clearly modulate
disease severity in the S63del-CMT1B neuropathy, they do
not appear to exert any essential role in physiological PNS
myelination. In fact, upon ablation of these UPR mediators
wild-type nerves develop normally and do not display myelin
defects (Pennuto et al., 2008; D’Antonio et al., 2013; Musner
et al., 2016; Sidoli et al., 2016), suggesting that they exert
a pivotal role only when Schwann cells are already under
stress.
Treatments Targeting the ERQC in
Myelinating Disorders
All myelin disorders described above are caused by mutations
leading to proteinmisfolding, impaired protein trafficking and/or
activation of ER stress/UPR (summarized in Table 1). In all these
diseases, the basal ERQC systems can be overwhelmed and the
adaptive stress responses may become insufficient to prevent
pathogenesis. In recent years, numerous studies have shown
that enhancing ERQC pathways and the folding/degradation of
proteins may provide a feasible and efficient therapeutic strategy
in conformational diseases.
Pharmacological treatments boosting the UPR/ISR by
inhibiting GADD34 have been used successfully in various
preclinical models of neurological disorders (Hetz et al., 2013).
For example, salubrinal restores motor function and ameliorates
morphological and electrophysiological parameters in S63del
mice (D’Antonio et al., 2013). Targeting the same pathway is
also beneficial in a model of multiple sclerosis. Enhancement
of PERK signaling by a genetic approach or sustained eIF2α
phosphorylation with the GADD34 inhibitor guanabenz protects
oligodendrocytes from death induced by EAE (Tsaytler et al.,
2011; Lin et al., 2013; Way et al., 2015). Recently, Sephin1, a more
specific GADD34 inhibitor, has been shown to largely prevent
the motor, morphological, and molecular defects of S63del mice
(Das et al., 2015). Finally, Sephin1 treatment has also been
applied with success in the mutant SOD1G93A mouse model of
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amyotrophic lateral sclerosis (ALS), a motor neuron disease. In
this model, Sephin1 administration attenuates motor deficits and
motor neuron loss, decreases the aggregation of mutant SOD1
and the level of ER stress (Das et al., 2015).
Pharmacological chaperone therapy (PCT) is another
emerging approach that may be used to enhance ERQC in
protein misfolding diseases. It is based on the administration
of exogenous small-molecules that selectively bind mutant
proteins and rescue their function by preventing aggregation
and degradation and by promoting their trafficking. In lysosomal
storage disorders, PCT clinical trials have produced encouraging
results as a mono-therapy or in combination therapy (Parenti
et al., 2015). PCT has not been tested yet in patients with
inherited demyelinating disorders, however several studies
highlight the potential of this approach. Treatment of KD cells
with the chemical chaperone 4-phenylbutyric acid (4-PBA)
increases the level and activity of GALC and promotes the
trafficking of GALC mutants to the lysosomes (Shin et al.,
2016). In another cell model of KD, treatment with N-octyl-4-
epi-valienamine (NOEV) significantly increases the enzymatic
activity and the processing of late-onset GALCmutants (Hossain
et al., 2015). Moreover, administration of curcumin, a small
molecule derived from the spice turmeric, known to correct
the misfolding defects in models of cystic fibrosis (Egan et al.,
2004), lowers mutant protein retention and the expression
of UPR markers, and partially alleviates disease severity of
in vitro and in vivo models of CMT1B and CMT1E (Khajavi
et al., 2005, 2007; Patzkó et al., 2012; Okamoto et al., 2013).
Curcumin therapy also leads to a modest amelioration of
the phenotype in msd and PLP1 transgenic mouse models
of PMD (Yu et al., 2012; Epplen et al., 2015), although the
molecular mechanisms underlying curcumin action are still
largely unknown.
Concluding Remarks
The accurate control of proper protein folding, maturation and
trafficking is emerging as a key determinant in the physiology
of myelinating glia. Several dysmyelinating disorders in both the
CNS and the PNS show an important involvement of ER protein
quality control systems in disease pathogenesis. However, each
disease (and often each mutation) presents a unique signature in
terms of ERQC pathways activation and mutant protein disposal
(Table 1). A better understanding of the importance of each of
these stress signaling pathways in physiological myelination and
in disease will be crucial for the rational design of therapeutic
strategies aimed at curing these often devastating conditions.
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